Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Intangibles (2017 - 2024)

Historic Intangibles for Innate Pharma (IPHYF) over the last 8 years, with Q2 2024 value amounting to $128149.6.

  • Innate Pharma's Intangibles fell 8696.74% to $128149.6 in Q2 2024 from the same period last year, while for Jun 2024 it was $128149.6, marking a year-over-year decrease of 8696.74%. This contributed to the annual value of $447591.0 for FY2023, which is 7180.54% down from last year.
  • As of Q2 2024, Innate Pharma's Intangibles stood at $128149.6, which was down 8696.74% from $447591.0 recorded in Q4 2023.
  • Innate Pharma's 5-year Intangibles high stood at $95.2 billion for Q2 2020, and its period low was $128149.6 during Q2 2024.
  • For the 5-year period, Innate Pharma's Intangibles averaged around $10.6 billion, with its median value being $46.2 million (2022).
  • Over the last 5 years, Innate Pharma's Intangibles had its largest YoY gain of 839.92% in 2021, and its largest YoY loss of 9994.28% in 2021.
  • Innate Pharma's Intangibles (Quarter) stood at $55.2 million in 2020, then dropped by 8.4% to $50.6 million in 2021, then crashed by 96.86% to $1.6 million in 2022, then plummeted by 71.81% to $447591.0 in 2023, then plummeted by 71.37% to $128149.6 in 2024.
  • Its Intangibles stands at $128149.6 for Q2 2024, versus $447591.0 for Q4 2023 and $983298.6 for Q2 2023.